Anti-LYPD1/ LYPDC1/ PHTS monoclonal antibody

Anti-LYPD1/ LYPDC1/ PHTS antibody for FACS & in-vivo assay

Target products collectionGo to LYPD1/LYPD1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0782-Ab-1/ GM-Tg-hg-MP0782-Ab-2Anti-Human LYPD1 monoclonal antibodyHuman
GM-Tg-rg-MP0782-Ab-1/ GM-Tg-rg-MP0782-Ab-2Anti-Rat LYPD1 monoclonal antibodyRat
GM-Tg-mg-MP0782-Ab-1/ GM-Tg-mg-MP0782-Ab-2Anti-Mouse LYPD1 monoclonal antibodyMouse
GM-Tg-cynog-MP0782-Ab-1/ GM-Tg-cynog-MP0782-Ab-2Anti-Cynomolgus/ Rhesus macaque LYPD1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0782-Ab-1/ GM-Tg-felg-MP0782-Ab-2Anti-Feline LYPD1 monoclonal antibodyFeline
GM-Tg-cang-MP0782-Ab-1/ GM-Tg-cang-MP0782-Ab-2Anti-Canine LYPD1 monoclonal antibodyCanine
GM-Tg-bovg-MP0782-Ab-1/ GM-Tg-bovg-MP0782-Ab-2Anti-Bovine LYPD1 monoclonal antibodyBovine
GM-Tg-equg-MP0782-Ab-1/ GM-Tg-equg-MP0782-Ab-2Anti-Equine LYPD1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0782-Ab-1/ GM-Tg-hg-MP0782-Ab-2; GM-Tg-rg-MP0782-Ab-1/ GM-Tg-rg-MP0782-Ab-2;
GM-Tg-mg-MP0782-Ab-1/ GM-Tg-mg-MP0782-Ab-2; GM-Tg-cynog-MP0782-Ab-1/ GM-Tg-cynog-MP0782-Ab-2;
GM-Tg-felg-MP0782-Ab-1/ GM-Tg-felg-MP0782-Ab-2; GM-Tg-cang-MP0782-Ab-1/ GM-Tg-cang-MP0782-Ab-2;
GM-Tg-bovg-MP0782-Ab-1/ GM-Tg-bovg-MP0782-Ab-2; GM-Tg-equg-MP0782-Ab-1/ GM-Tg-equg-MP0782-Ab-2
Products NameAnti-LYPD1 monoclonal antibody
Formatmab
Target NameLYPD1
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LYPD1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LYPD1/ LYPDC1/ PHTS VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0782
    Target NameLYPD1
    Gene ID116372,72585,360838,709476,610707,101088178,533675,100050290
    Gene Symbol and Synonyms2700050C12Rik,C530008O16Rik,Lynx2,LYPD1,LYPDC1,PHTS
    Uniprot AccessionQ8N2G4,Q66H42
    Uniprot Entry NameLYPD1_HUMAN,LYPD1_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000150551
    Target ClassificationN/A

    The target: LYPD1, gene name: LYPD1, also named as LYPDC1, PHTS. Predicted to enable acetylcholine receptor binding activity and acetylcholine receptor inhibitor activity. Predicted to be involved in acetylcholine receptor signaling pathway. Predicted to act upstream of or within several processes, including behavioral fear response; cholinergic synaptic transmission; and negative regulation of protein localization to plasma membrane. Predicted to be located in membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.